Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024
27 oct. 2024 08h15 HE
|
HeartFlow Holding, Inc.
— Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronary artery disease -– FFRCT further...
HeartFlow Announces Favorable Coverage Determination for Plaque Analysis by Four Medicare Administrative Contractors
11 oct. 2024 12h27 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the global leader in non-invasive artificial intelligence (AI) heart care solutions, today announced HeartFlow Plaque...
HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease
18 juil. 2024 09h00 HE
|
HeartFlow Holding, Inc.
Technology offers benefits of HeartFlow Plaque Analysis with the new addition of 3D interactive capabilities, integrated with lesion specific FFRCT values WASHINGTON, July 18, 2024 (GLOBE...
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
16 juil. 2024 12h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on...
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
03 juin 2024 12h00 HE
|
HeartFlow Holding, Inc.
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
HeartFlow's Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study
15 mai 2024 12h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its...
HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease
26 mars 2024 14h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in AI-driven healthcare technology, today announced the launch of the DECIDE Registry, the largest prospective...
HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis
03 janv. 2024 09h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has...
TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights
25 oct. 2023 11h00 HE
|
HeartFlow Holding, Inc.
New Clinical Data Support Use of Lesion-Specific FFRCT for Diagnosis and Treatment of Patients With Coronary Artery Disease
HeartFlow Receives FDA 510(k) Clearance for its Plaque Analysis and RoadMap™ Analysis
18 oct. 2022 10h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, has received U.S. Food and Drug Administration (FDA) 510(k) clearance on...